Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk

Pain Practice

Volumn 14, Issue 4, 2014, Pages 378-395

  Moore, Robert Andrew ^a   Derry, Sheena ^a   Simon, Lee S ^b   Emery, Paul ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SDG LLC   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Gastroprotection; Joint pain; Nonsteroidal anti inflammatory drugs; NSAID; Pain; Risk benefit analysis; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FAMOTIDINE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXYCODONE; PANTOPRAZOLE; PLACEBO; RANITIDINE; TAPENTADOL;

ANALGESIA; ANKYLOSING SPONDYLITIS; ARTICLE; ATTITUDE TO HEALTH; BREAKTHROUGH PAIN; CHRONIC PAIN; DAILY LIFE ACTIVITY; DRUG EFFICACY; DUODENUM ULCER; FIBROMYALGIA; HUMAN; LOW BACK PAIN; MEDICATION COMPLIANCE; META ANALYSIS; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; POSTOPERATIVE PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STOMACH PROTECTION; STOMACH ULCER; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84897373459     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12100     Document Type: Review

References (130)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-2196.
2. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia. 2013 Jan 24; 68:400-412.
3. Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169-182.
4. Hawkey CJ. Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut. 2002;50(Suppl 3):III25-III30.
5. Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51, 000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15:R6.
6. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093-2099.
7. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592-1601.
8. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2004;54:320-326.
9. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731-1738.
10. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132:498-506.
11. Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7:79.
12. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;8:73.
13. Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41.
14. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
15. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians; 2008.
16. Laharie D, Droz-Perroteau C, Bénichou J, et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010;69:295-302.
17. Miyamoto M, Haruma K, Okamoto T, Higashi Y, Hidaka T, Manabe N. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J Gastroenterol Hepatol 2012;27:372-377.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
19. Moore RA, Eccleston C, Derry S et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain. 2010;150:386-389.
20. Moore RA, Straube S, Eccleston C, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain. 2012;153:265-268.
21. Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA. Searching one or two databases was insufficient for meta-analysis of observational studies. J Clin Epidemiol. 2005;58:867-873.
22. Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology. 2006;105:394-399.
23. Park CL, Roberts DE, Aldington DJ, Moore RA. Prehospital analgesia: systematic review of evidence. J R Army Med Corps 2010;156(4 Suppl 1):295-300.
24. Moore A, McQuay H. Bandolier's Little Book of Making Sense of the Medical Evidence. Oxford: Oxford University Press; 2006.
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
26. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
27. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG, eds. Statistics With Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ; 1995:50-63.
28. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
29. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315:635-640.
30. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia. 2013;68:400-412.
31. Dougados M. It's good to feel better but it's better to feel good. J Rheumatol. 2005;32:1-2.
32. O'Brien EM, Staud RM, Hassinger AD, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Med. 2010;11:6-15.
33. Brown JL, Edwards PS, Atchison JW, Lafayette-Lucey A, Wittmer VT, Robinson ME. Defining patient-centered, multidimensional success criteria for treatment of chronic spine pain. Pain Med. 2008;9:851-862.
34. Stutts LA, Robinson ME, McCulloch RC, et al. Patient-centered outcome criteria for successful treatment of facial pain and fibromyalgia. J Orofac Pain. 2009;23:47-53.
35. Thorne FM, Morley S. Prospective judgments of acceptable outcomes for pain, interference and activity: patient-determined outcome criteria. Pain. 2009;144:262-269.
36. Farrar JT, Polomano RC, Berlin JA, Strom BL. A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology. 2010;112:1464-1472.
37. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8:283-291.
38. Mease PJ, Spaeth M, Clauw DJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken). 2011;63:821-826.
39. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287-294.
40. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557-560.
41. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005;64:34-37.
42. Ornetti P, Dougados M, Paternotte S, Logeart I, Gossec L. Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with the WOMAC function scale. Ann Rheum Dis. 2011;70:740-746.
43. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121.
44. Simon LS, Evans C, Katz N, et al. Preliminary development of a responder index for chronic low back pain. J Rheumatol. 2007;34:1386-1391.
45. Dixon S, Poole CD, Odeyemi I, Retsa P, Chambers C, Currie CJ. Deriving health state utilities for the numerical pain rating scale. Health Qual Life Outcomes. 2011;9:96.
46. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-379.
47. Barthel HR, Peniston JH, Clark MB, Gold MS, Altman RD. Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis. Arthritis Res Ther. 2010;12:R7.
48. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain. 2010;151:592-597.
49. Peloso PM, Gammaitoni A, Smugar SS, Wang H, Moore RA. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord. 2011;12:165.
50. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskelet Disord. 2010;11:150.
51. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011;152:982-989.
52. Christakis NA. Does this work for you? BMJ. 2008;337:a2281.
53. Moore RA, Derry S, Taylor RS, Straube S, Phillips C. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice. 2013; doi:10.1111/papr.12050. [Epub ahead of print].
54. Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res (Hoboken). 2010;62:1399-1406.
55. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain. 2010;149:194-201.
56. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain. 2010;149:360-364.
57. Ikenberg R, Hertel N, Moore RA, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ. 2012;15:724-736.
58. Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care. 2006;22:235-241.
59. Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006;10:1-183.
60. Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis. 2000;32:201-208.
61. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12:135-140.
62. Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996;31:753-758.
63. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169-175.
64. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-734.
65. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32:401-413.
66. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997;112:1817-1822.
67. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435-1439.
68. ten Wolde S, Dijkmans BA, Janssen M, Hermans J, Lamers CB. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther. 1996;10:347-351.
69. Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012;107:379-386.
70. Lazebnik LB, Drozdov VN, Kim VA. Efficiency of famotidine in prophylaxis of NSAIDs-induced gastropathy: result of multicenter research ZASLON-1 (protection of gastric mucosa from non-steroidal anti-inflammatory drugs [Article in Russian]. Eksp Klin Gastroenterol. 2009;2:3-9.
71. Goldstein JL, Johanson JF, Hawkey CJ, Suchowers LJ, Brown KA. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther. 2007;26:1101-1111.
72. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719-726.
73. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol. 2010;16:5342-5346.
74. Lanas A, García-Rodríguez LA, Arroyo MT et al.Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507-515.
75. Nakamura H, Yokoyama H, Yaguchi T, et al. Investigation into the effect of gastric secretion inhibitor for the prevention of upper gastrointestinal lesions associated with low-dose aspirin [Article in Japanese]. Yakugaku Zasshi. 2011;131:445-452.
76. Bell JS, Taipale HT, Soini H, Pitkälä KH. Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record review. Clin Drug Investig. 2011;31:337-344.
77. Bianco MA, Rotondano G, Buri L, Tessari F, Cipolletta L. Gastro-protective strategies in primary care in Italy: the "Gas.Pro". survey. Dig Liver Dis. 2010;42:359-364.
78. Coté GA, Norvell JP, Rice JP, Bulsiewicz WJ, Howden CW. Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugs. Am J Ther. 2008;15:444-449.
79. Doherty GA, Cannon MD, Lynch KM, et al. Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do. J Clin Gastroenterol. 2010;44:e51-e56.
80. Helsper CW, Smeets HM, Numans ME, Knol MJ, Hoes AW, de Wit NJ. Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Pharmacoepidemiol Drug Saf. 2009;18:800-806.
81. Johnell K, Fastbom J. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study. Clin Drug Investig. 2008;28:687-695.
82. Koncz TA, Lister SP, Makinson GT. Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization. Curr Med Res Opin. 2008;24:3405-3412.
83. Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011;9:38.
84. Lanas A, Munoz M, Caballero Correa M, Martinez Jimenez P, investigadores del estudio GAP. Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study. (Article in Spanish). Gastroenterol Hepatol. 2010;33:80-91.
85. Ljung R, Lu Y, Lagergren J. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging. 2011;28:469-476.
86. López-Pintor E, Lumbreras B. Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies. Int J Clin Pharm. 2011;33:155-164.
87. Morini S, Zullo A, Oliveti D, et al. A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol. 2011;45:780-784.
88. Pasina L, Nobili A, Tettamanti M, et al. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions. Int J Clin Pharmacol Ther. 2010;48:735-743.
89. Thiéfin G, Schwalm MS. Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs. Dig Liver Dis. 2011;43:209-214.
90. Tsumura H, Fujita T, Tamura I, et al. Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients. J Gastroenterol. 2010;45:944-951.
91. Valkhoff VE, van Soest EM, Sturkenboom MC, Kuipers EJ. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther. 2010;31:1218-1228.
92. Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A population-based study. Arthritis Rheum. 2012;64:2792-2802.
93. Valkhoff VE, van Soest EM, Masclee GM, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617 400-patient study. Aliment Pharmacol Ther. 2012;36:790-799.
94. van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26:265-275.
95. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011;60:1650-1659.
96. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009;25:195-204.
97. Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137-1147.
98. Lanas A, Polo-Tomás M, Roncales P, Gonzalez MA, Zapardiel J. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol. 2012;107:707-714.
99. Vestergaard P, Hermann P, Jensen JE, Eiken P, Mosekilde L. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23:1255-1265.
100. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997;44:85-90.
101. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968-1976.
102. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302-1308.
103. Torrance N, Elliott AM, Lee AJ, Smith BH. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain. 2010;14:380-386.
104. Sokka T, Pincus T. Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care. BMJ Open. 2011;1:e000070.
105. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.
106. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367-372.
107. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol. 2010;69:689-700.
108. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768-776.
109. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9:257-267.
110. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209-1218.
111. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22:903-910.
112. Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794-800.
113. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519-526.
114. Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.
115. Mello M, Weideman RA, Little BB, Weideman MW, Cryer B, Brown GR. Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci. 2012;57:2416-2422.
116. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33:843-852.
117. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93-114.
118. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5:219-232.
119. Robertson DJ, Burke CA, Schwender BJ, et al. Histamine receptor antagonists and incident colorectal adenomas. Aliment Pharmacol Ther. 2005;22:123-128.
120. Moore RA, Derry S, McQuay HJ, Paling J. What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. Arthritis Res Ther. 2008;10:R20.
121. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: a randomized trial. Ann Intern Med. 2011;155:87-96.
122. Johnson FR, Ozdemir S, Hauber B, Kauf TL. Women's willingness to accept perceived risks for vasomotor symptom relief. J Womens Health (Larchmt). 2007;16:1028-1040.
123. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769-779.
124. Richardson CG, Chalmers A, Llewellyn-Thomas HA, Klinkhoff A, Carswell A, Kopec JA. Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol. 2007;34:1569-1575.
125. Hauber AB, Arden NK, Mohamed AF, et al. A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage. 2013;21:289-297.
126. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554-562.
127. Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S. Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother 2010;44:479-488.
128. Johnson FR, Hauber AB, Ozdemir S, Lynd L. Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health. 2010;13:418-423.
129. Arden NK, Hauber AB, Mohamed AF, et al. How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom? J Rheumatol. 2012;39:1056-1063.
130. Conaghan PG, Rannou F, Phillips CJ, et al. A Survey of Osteoarthritis Real World Therapies (SORT): Assessing the Impact of Inadequate Pain Relief (IPR) on Quality of Life, Work Productivity and Health Resource Utilization in Patients with Knee Osteoarthritis. 14th World Congress on Pain, Milan, Italy, August 27-31, 2012. Poster No. PF 117.